Sinopharm Group Co. Ltd (X2S) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.023x

Based on the latest financial reports, Sinopharm Group Co. Ltd (X2S) has a cash flow conversion efficiency ratio of -0.023x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.63 Billion ≈ $-3.08 Billion USD) by net assets (€113.11 Billion ≈ $132.24 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sinopharm Group Co. Ltd (X2S) market capitalisation for the company's overall valuation and market capitalisation.

Sinopharm Group Co. Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Sinopharm Group Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Sinopharm Group Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sinopharm Group Co. Ltd ranked by their cash flow conversion efficiency. Explore X2S cash flow quality score to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
XiaMen HongXin Electron-tech Co Ltd
SHE:300657
-0.082x
Zhejiang Kaishan Compressor
SHE:300257
0.028x
Tongling Jingd
SHG:600577
0.065x
First Merchants Corporation
NASDAQ:FRME
0.033x
Guangshen Railway Co Ltd
SHG:601333
0.009x
Qingdao Gon Technology Co Ltd
SHE:002768
0.007x
GOLDEN AGRI-RES ADR/100
F:4G3
N/A
CareDx Inc
NASDAQ:CDNA
0.072x

Annual Cash Flow Conversion Efficiency for Sinopharm Group Co. Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Sinopharm Group Co. Ltd from 2013 to 2025. View Sinopharm Group Co. Ltd (X2S) share price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €134.16 Billion
≈ $156.85 Billion
€14.14 Billion
≈ $16.53 Billion
0.105x +15.63%
2024-12-31 €126.69 Billion
≈ $148.11 Billion
€11.55 Billion
≈ $13.50 Billion
0.091x -36.15%
2023-12-31 €120.32 Billion
≈ $140.67 Billion
€17.17 Billion
≈ $20.08 Billion
0.143x -25.06%
2022-12-31 €110.07 Billion
≈ $128.68 Billion
€20.96 Billion
≈ $24.51 Billion
0.190x +103.91%
2021-12-31 €99.65 Billion
≈ $116.51 Billion
€9.31 Billion
≈ $10.88 Billion
0.093x -24.68%
2020-12-31 €89.95 Billion
≈ $105.16 Billion
€11.15 Billion
≈ $13.04 Billion
0.124x -49.19%
2019-12-31 €76.94 Billion
≈ $89.95 Billion
€18.78 Billion
≈ $21.95 Billion
0.244x +356.05%
2018-12-31 €68.28 Billion
≈ $79.82 Billion
€3.65 Billion
≈ $4.27 Billion
0.054x -14.49%
2017-12-31 €51.27 Billion
≈ $59.94 Billion
€3.21 Billion
≈ $3.75 Billion
0.063x -69.90%
2016-12-31 €44.53 Billion
≈ $52.06 Billion
€9.26 Billion
≈ $10.82 Billion
0.208x -36.64%
2015-12-31 €40.88 Billion
≈ $47.79 Billion
€13.41 Billion
≈ $15.68 Billion
0.328x +114.12%
2014-12-31 €36.29 Billion
≈ $42.43 Billion
€5.56 Billion
≈ $6.50 Billion
0.153x -11.27%
2013-12-31 €28.61 Billion
≈ $33.45 Billion
€4.94 Billion
≈ $5.78 Billion
0.173x --

About Sinopharm Group Co. Ltd

F:X2S Germany Medical Distribution
Market Cap
$2.59 Billion
€2.21 Billion EUR
Market Cap Rank
#5362 Global
#853 in Germany
Share Price
€1.65
Change (1 day)
-0.57%
52-Week Range
€1.65 - €2.37
All Time High
€2.71
About

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical … Read more